Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2013

01-12-2013 | Clinical Guides in Oncology

SEOM clinical guidelines for the management of metastatic breast cancer 2013

Authors: A. Llombart Cussac, J. de la Haba Rodríguez, A. Ruiz Simón, I. Álvarez López, J. Cortés Castán

Published in: Clinical and Translational Oncology | Issue 12/2013

Login to get access

Abstract

Patients with metastatic breast cancer should be offered comprehensive and personalized medical attention including, but not limited to, psychosocial, supportive and symptom-related interventions. A large number of treatment options are available and several prognostic and predictive factors are useful to identify the best therapeutic options individually.
Appendix
Available only for authorised users
Literature
1.
2.
Alvarez-Lopez I, de la Haba-Rodríguez J, Ruiz-Simón A, Bellet Ezquerra M, Calvo Martínez L, García Estévez L, et al. SEOM clinical guidelines for the treatment of metastatic breast cancer. Clin Transl Oncol. 2010;12:719–23.PubMedCrossRef
3.
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21:242–52.PubMedCrossRef
4.
Cardoso F, Castiglione M, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO. Clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;4(Suppl 2):15–8.
5.
6.
Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.PubMedCrossRef
7.
Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012;23:1378–86.PubMedCrossRef
8.
Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat. 2012;136:503–11.PubMedCrossRef
9.
Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30:1919–25.PubMedCrossRef
10.
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367:435–44.PubMedCrossRef
11.
Johnston SR. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. Eur J Cancer. 2011;47(Suppl 3):S38–47.PubMedCrossRef
12.
Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.PubMedCrossRef
13.
Cortes J, Calvo E, Gonzalez-Martin A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, et al. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol. 2012;30:3444–7.PubMedCrossRef
14.
Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol. 2011;12:1053–61.PubMedCrossRef
15.
Montero AJ, Adams B, Diaz-Montero CM, Glück S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol. 2011;4:329–34.PubMedCrossRef
16.
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914–23.PubMedCrossRef
17.
Nielsen DL, Kümler I, Palshof JA, Andersson M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast. 2013;22:1–12.PubMedCrossRef
18.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.PubMedCrossRef
19.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, EMILIA Study Group, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.PubMedCrossRef
20.
Cassinello Espinosa J, González Del Alba Baamonde A, Rivera Herrero F, Holgado Martín E; SEOM (Spanish Society of Clinical Oncology). SEOM guidelines for the treatment of bone metastases from solid tumours. Clin Transl Oncol. 2012;14:505–11.
21.
Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, et al. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol. 2010;17:2419–26.PubMedCrossRef
Metadata
Title
SEOM clinical guidelines for the management of metastatic breast cancer 2013
Authors
A. Llombart Cussac
J. de la Haba Rodríguez
A. Ruiz Simón
I. Álvarez López
J. Cortés Castán
Publication date
01-12-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1095-0

Other articles of this Issue 12/2013

Clinical and Translational Oncology 12/2013 Go to the issue

Clinical Guides in Oncology

SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013

Clinical Guides in Oncology

SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013

Clinical Guides in Oncology

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits